The increase in price target by Goldman Sachs suggests a positive outlook on the value of Eli Lilly and Co, potentially leading to increased investor confidence and a short-term positive impact on the stock price. The Neutral rating indicates that the stock might not have significant upside or downside from its current level, but the raised target suggests an improved valuation perspective.